Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 May 25;91(S-5):23-29.
doi: 10.23750/abm.v91iS-5.9914.

Hodgkin's lymphoma: post- autologous transplantation consolidation therapy

Francesco Merli  1 , Filippo Ballerini  2 , Barbara Botto  3 , Manuel Gotti  4 , Vincenzo Pavone  5 , Alessandro Pulsoni  6 , Pietro Maria Stefani  7 , Fulvio Massaro  1 , Simonetta Viviani  8
Affiliations
Case Reports

Hodgkin's lymphoma: post- autologous transplantation consolidation therapy

Francesco Merli et al. Acta Biomed. .

Abstract

A first-line chemotherapy program based on the ABVD regimen is currently considered the golden standard by most hematologists, being able to achieve a cure without any need of subsequent therapies in >70% of patients with advanced-stage Hodgkin's lymphoma (HL). To increase this percentage, efforts in recent decades focused on the development of new therapeutic strategies. A first major effort was the introduction of the BEACOPP chemotherapy regimen, which is able to increase the response rate and to reduce the need of salvage therapies. However, this result did not demonstrate an advantage in terms of overall survival compared to ABVD, mainly due to an excess of non lymphoma-related events in the follow-up phase. Here we describe three clinical cases of young HL patients who had relapsed/refractory disease after the induction chemotherapy. These three clinical cases provide practical and real world evidence in favor of the use of BV in monotherapy as consolidation treatment after autologous stem cells transplantation in patients with relapsed/refractory HL.

PubMed Disclaimer

Conflict of interest statement

Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article

References

    1. Viviani S, Zinzani PL, Rambaldi A, et al. Intergruppo Italiano Linfomi. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203–212. - PubMed
    1. Merli F, Luminari S, Gobbi PG, et al. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fon-dazione Italiana Linfomi. J Clin Oncol. 2016;34(11):1175–1181. - PubMed
    1. Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016;374(25):2419–2429. - PMC - PubMed
    1. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-di-rected therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372(17):1598–1607. - PubMed
    1. Schmitz N, Pfistner B, Sextro M, et al. Lym-phoma Working Party of the European Group for Blood and Marrow Transplantation. Ag-gressive conventional chemotherapy compared with high-dose chemo-therapy with autologous haemopoietic stem-cell trans-plantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–2071. - PubMed

Publication types